GlassScriptPhysician profile
Christopher Aghedo
NPI 1831472109
$1,488.39
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.36 · 2023: $483 · 2024: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $261.62 | 2023-2024 | Ingrezza |
| Alkermes, INC. | $250.39 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $247.45 | 2023-2024 | Austedo Xr, Uzedy |
| Abbvie INC. | $215.61 | 2023-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $149.49 | 2023-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Ironshore Pharmaceuticals INC. | $92.59 | 2023-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.46 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $46.14 | 2023-2024 | Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $37.60 | 2024 | Cobenfy |
| Vanda Pharmaceuticals INC. | $29.72 | 2024 | Hetlioz, Fanapt |
| Tempus Ai, INC | $24.41 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.24 | 2023 | Trintellix |
| Corium, LLC | $14.36 | 2022 | |
| Lundbeck LLC | $14.28 | 2023 | Rexulti |
| Indivior INC. | $14.03 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Aghedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.